Clinical trials: Complete Response
Breast Cancer
Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer
The purpose of this study is to evaluate the pathological complete response (pCR) rate in breast cancer patients treated with weekly paclitaxel plus carboplatin preoperative regimen.
- Trial name
- NCT01203267
- Testing
- Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00163306
- Testing
- Pantoprazole
- Where
- 79 sites in Austria, Germany and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Breast Cancer
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
The aim of this study was to evaluate the efficacy, safety and tolerability of lobaplatin versus carboplatin as neoadjuvant therapy for stage II / III HER-2 positive breast cancer.
- Trial name
- NCT07093931
- Testing
- lobaplatin, carboplatin, Docetaxel or albumin paclitaxel
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Shandong Cancer Hospital and Institute
Pathological Complete Remission, Objective Response Rate
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant…
- Conditions
- Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
- Trial name
- NCT07430579
- Testing
- adebrelimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The Second Hospital of Shandong University
Rectal Cancer
Organ Preservation in Elderly Patients With Rectal Cancer
In elderly patients postoperative mortality measured 3-6 months after total mesorectal excision is high. Thus, less toxic treatments may lead to a survival benefit for elderly patients even if a risk of local recurrence is…
- Trial name
- NCT01863862
- Testing
- Radiochemotherapy or radiotherapy
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Ovarian Cancer
Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002977
- Testing
- filgrastim, melphalan, thiotepa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Hepatitis C, Chronic, Hepatitis C
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of liver histology and inhibition of progression to liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT00787371
- Testing
- PegIntron (peginterferon alfa-2b)
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
Myelogenous Leukemia, Chronic, Chronic Phase
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission(CMR) while on…
- Trial name
- NCT01887561
- Testing
- dasatinib
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kanto CML Study Group
BRCA1 Mutation, Breast Cancer Invasive Nos
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland
This is a single center, non-randomized, open label phase II trial to evaluate the clinical and pathologic response of neoadjuvant cisplatin-monotherapy in BRCA1 positive patients.
- Trial name
- NCT01630226
- Testing
- Neoadjuvant Cisplatin Chemotherapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Cervical Cancer
Thunderbeat Technology vs Standard Bipolar Electro Surgery in Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy for Cervical Cancer
This prospective randomized pilot study is aimed to verify if the operative time of a LRH with pelvic lymphadenectomy for early stage cervical cancer (FIGO stages IA2-IB1-IIA<2cm) and for advanced stage cervical cancer (FIGO…
- Trial name
- Thunder Cervix (NCT01717781)
- Testing
- Thunderbeat technology, Standard bipolar electrosurgery
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Catholic University of the Sacred Heart
Breast Cancer, HER2-positive Breast Cancer
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
At present, the incidence rate of breast cancer has exceeded that of lung cancer, becoming the largest cancer in the world. HER2 overexpression breast cancer accounts for about 20%~30% of all breast cancer patients.
- Trial name
- NCT05918328
- Testing
- Albumin paclitaxel+trastuzumab+pyrrolitinib, Docetaxel+Carboplatin+trastuzumab+Parstuzumab
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer
Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have extensive-stage small cell lung cancer that…
- Trial name
- NCT00053300
- Testing
- thalidomide, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
This phase II trial studies how well pUMVC3-IGFBP2 plasmid deoxyribonucleic acid (DNA) vaccine (IGFBP-2 vaccine) and combination chemotherapy work in treating patients with stage III-IV ovarian, fallopian tube, or primary…
- Conditions
- Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer
- Trial name
- NCT03029611
- Testing
- Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Washington
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC (Non-small Cell Lung Cancer)
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy…
- Trial name
- NCT06939127
- Testing
- Neoadjuvant Cryoablation Combined with Tislelizumab and Chemotherapy, Surgery, Adjuvant tislelizumab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hodgkin Lymphoma in Remission
Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: in complete…
- Trial name
- MEPI-AGE (NCT06761274)
- Testing
- peripheral blood sampling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
This is an open-label, multicenter, randomized phase 3 trial. Eligible patients are women with cN3 breast cancer who have completed neoadjuvant systemic therapy (NST), undergone breast/axillary surgery with the internal mammary…
- Trial name
- NCT07805538
- Testing
- Standard Boost., Boost Omission
- Where
- China
- Sponsor
- Fudan University
Rectal Cancer
Radical vs Local Excision for Rectal Cancer With Clinically Complete Remission
In the present project, the investigators plan to more accurately select the rectal cancer patients with pathological complete response (pCR) to preoperative concomitant chemoradiation therapy (CCRT), taking advantage of…
- Trial name
- NCT05964530
- Testing
- Surgery
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Triple Negative Breast Cancer
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Italian, multicenter, open-label, two-arm, comparative, randomized phase II study investigating if the addition of the experimental metabolic intervention consisting in cycles of Fasting-Like Approach, as administered every three…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting
- Trial name
- BREAKFAST-2 (NCT05763992)
- Testing
- Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
- Where
- Italy
- Volunteers
- 145 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Rectal Cancer Patients
Impact Of Metformin In Rectal Cancer Patients
Design: Prospective, randomized controlled clinical trial Setting: at Minia University Hospital and Minia Oncology Institute. Condition: Colorectal cancer.
- Trial name
- NCT06728982
- Testing
- Metformin
- Where
- 2 sites in Egypt
- Volunteers
- 85 people
- Sponsor
- Minia University